Korean J Med.  2017 Apr;92(2):162-170. 10.3904/kjm.2017.92.2.162.

The Effect of Naïve Tenofovir Dipivoxil Fumarate Monotherapy in Patients with Chronic Hepatitis B: 2-Year Results of a Real-world Single-center Study

Affiliations
  • 1Department of Internal Medicine, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea. green740@kyuh.ac.kr

Abstract

BACKGROUND/AIMS
An incomplete virological response has been observed to tenofovir dipivoxil fumarate (TDF) in nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients. This study investigated the efficacy of TDF in NA-naïve CHB patients 96 weeks after treatment.
METHODS
CHB patients treated with TDF were enrolled retrospectively between November 2012 and January 2016. We assessed virological and biochemical parameters.
RESULTS
The study enrolled 179 NA-naïve patients with a median follow-up duration of 59.6 weeks. The serum hepatitis B virus (HBV) DNA level decreased significantly during treatment. The complete virological response (CVR) rate was 83.21% at week 96. In univariate analyses, the predictors of a CVR at 96 weeks were the baseline HBV DNA level (CVR vs. no-CVR, HBV DNA log10 mean value 7.34 vs. 7.86, 95% confidential interval [CI]: -7.89 to -7.37; p < 0.001) and male sex (CVR vs. no-CVR, 49.1% vs. 81.3%, odds ratio [OR] 0.22, 95% CI: 0.06 to 0.87; p = 0.025). In the multivariate analysis, male sex predicted a CVR at week 96. The CVR was significantly lower in males than in females (OR 0.12, 95% CI: 0.02 to 0.96; p = 0.046).
CONCLUSIONS
TDF was effective for treating CHB for more than 2 years in NA-naïve patients.

Keyword

Tenofovir; Hepatitis B; Chronic

MeSH Terms

DNA
Female
Follow-Up Studies
Hepatitis B
Hepatitis B virus
Hepatitis B, Chronic*
Hepatitis, Chronic*
Humans
Male
Multivariate Analysis
Odds Ratio
Retrospective Studies
Tenofovir*
DNA
Tenofovir
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr